Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Roland Rapold"'
Autor:
Oliver Reich, Thomas Rosemann, Oliver Senn, Eva Blozik, Rahel Meier, Martin Scherer, Carola A Huber, Roland Rapold, Felix Huber, Jan von Overbeck, Felix Schneuwly, Daniel Tapernoux
Publikováno v:
BMJ Open, Vol 10, Iss 4 (2020)
Objectives The quality of ambulatory care in Switzerland is widely unknown. Therefore, this study aimed to evaluate the recently proposed quality indicators (QIs) based on a nationwide healthcare claims database and determine their association with t
Externí odkaz:
https://doaj.org/article/8323def38d0a4739a41c7dee93ec3f12
Autor:
Eva Blozik, Oliver Reich, Roland Rapold, Martin Scherer, Swiss Quality Indicator for Primary Care (SQIPRICA) Working Group
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background The level of quality of care of ambulatory services in Switzerland is almost completely unknown. By adapting existing instruments to the Swiss national context, the present project aimed to define quality indicators (QI) for the m
Externí odkaz:
https://doaj.org/article/edfd14d31e514ebc8abe23a1a00f2237
Autor:
Martin K. Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S. Bodmer, Silvan Locher, Michael A. Thiel, Roland Rapold, Maximilian Kuhn, Lucas M. Bachmann
Publikováno v:
BMC Ophthalmology, Vol 18, Iss 1, Pp 1-6 (2018)
Abstract Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest pub
Externí odkaz:
https://doaj.org/article/3c832f2edd414bf5925d00b7ef9e1cdb
Publikováno v:
BMC Ophthalmology, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Previous analyses of real-life data indicated that injection frequency and health care costs did not differ for anti-VEGF treatment with aflibercept and ranibizumab. The objective of this study was to investigate whether this find
Externí odkaz:
https://doaj.org/article/1d12f7a81aea46e6bd451c6040a20bde
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e105425 (2014)
To describe the prevalence and determinants of potentially inappropriate medication (PIM) use and association with hospitalizations in an elderly managed care population in Switzerland.Using health care claims data of four health insurers for a sampl
Externí odkaz:
https://doaj.org/article/c21919b64b27479d91de88fd38dadb10
Publikováno v:
International Journal of Integrated Care, Vol 12, Iss 1 (2012)
Introduction: This study investigates the efficiency gains of integrated care models in Switzerland, since these models are regarded as cost containment options in national social health insurance. These plans generate much lower average health care
Externí odkaz:
https://doaj.org/article/68bba2c6362b45b4949de9f0365b7e33
Publikováno v:
International Journal of Public Health. 65:969-979
We evaluated healthcare cost differences at the end of life (EOL) between language regions in Switzerland, accounting for a comprehensive set of variables, including treatment intensity. We evaluated 9716 elderly who died in 2014 and were insured at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aecff3619ce11fdb4f60e081b94aaa4c
https://doi.org/10.1007/s00038-020-01428-w
https://doi.org/10.1007/s00038-020-01428-w
Publikováno v:
BMC Ophthalmology, Vol 17, Iss 1, Pp 1-8 (2017)
BMC Ophthalmology
BMC Ophthalmology
Background Previous analyses of real-life data indicated that injection frequency and health care costs did not differ for anti-VEGF treatment with aflibercept and ranibizumab. The objective of this study was to investigate whether this finding persi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c0fbdc9f037dcb952cd3b2cb5595fe
http://link.springer.com/article/10.1186/s12886-017-0617-x
http://link.springer.com/article/10.1186/s12886-017-0617-x
Publikováno v:
Neuropsychiatric Disease and Treatment
Eva Blozik,1–3 Roland Rapold,1 Klaus Eichler,4 Oliver Reich1 1Department of Health Sciences, Helsana Group, Zürich, Switzerland; 2Institute of General Practice, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Division of General Pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7687bb920f35e7836b6c815693474082
https://doi.org/10.2147/ndt.s143180
https://doi.org/10.2147/ndt.s143180
BackgroundNovel drugs are dynamically changing current treatment regimens for multiple myeloma (MM). Novel drugs have improved prognosis of MM patients in clinical studies but are expensive. Little is known about up-to-date real-world application and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3e97102ef5a65ecc588933257282b3f
